Skip to Content

Docetaxel Mylan

Active Substance: docetaxel, anhydrous
Common Name: docetaxel
ATC Code: L01CD02
Marketing Authorisation Holder: Mylan S.A.S.
Active Substance: docetaxel, anhydrous
Status: Withdrawn
Authorisation Date: 2012-01-31
Therapeutic Area: Carcinoma, Non-Small-Cell Lung Prostatic Neoplasms Head and Neck Neoplasms Adenocarcinoma Breast Neoplasms
Pharmacotherapeutic Group: Antineoplastic agents

Therapeutic Indication

Treatment of breast cancer, special forms of lung cancer (non-small-cell lung cancer), prostate cancer, gastric cancer, or head and neck cancer.

The marketing authorisation for Docetaxel Mylan has lapsed becasue it has not been marketed in the European Union in the three years following the granting of the authorisation.

Source: European Medicines Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.